

Company name: Feminaï
Website www.feminaï.com
CEO name: Dr. Karny Ilan

CATEGORY: Medical Devices

SESSION: “AI as an Equalizer: From Center to Periphery in Healthcare.”

- **Executive Summary / Investment Rationale:** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Feminaï is a breast health technology company combining physiological data from wearable sensors with AI-driven analysis in a disposable self-exam patch. The platform expands access to accurate, affordable breast health screening. The company has raised \$10M, is backed by Vertex Ventures, holds international patents, and is led by a multidisciplinary team spanning biomedical engineering, AI, and clinical expertise.

- **Core Technology:** What is the technology, its uniqueness, and its value proposition?

Feminaï's core technology combines physiological parameters captured by wearable sensors with proprietary AI algorithms to analyze breast tissue changes. Delivered through a disposable self-exam patch, the system enables affordable, non-invasive assessment outside clinical settings, providing earlier, more accessible, and cost-effective breast health screening at population scale.

- **Product Profile/Pipeline:** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

The Feminaï Breast Examination Kit offers remote, disposable self-exams for breast health assessment. Following completed clinical trials in the U.S. and Israel, the company is progressing through FDA regulatory processes. Commercial launch is planned for year-end, supported by signed pilot programs with virtual care clinics and healthcare partners.

- **Business Strategy:** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Feminaï's initial go-to-market focuses on partnerships with virtual care and telemedicine providers, complemented by direct-to-consumer access. This approach enables rapid adoption and data generation. Longer term, the company plans to scale through collaborations with health payers and healthcare systems, supporting population-level breast health screening and preventive care models.

- **What's Next?** R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Near-term priorities include completing FDA regulatory review and initiating commercial pilots with virtual care partners. R&D efforts focus on expanding clinical evidence and improving AI performance. Organizational plans center on regulatory, clinical, and commercial growth.